Paper Details

  1. Home
  2. Paper Details

Near complete response to ceritinib in a pediatric patient with metastatic ALK-rearranged lung adenocarcinoma.

Author: HouXue, LiuMaolin, LiuZuhui

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.

Overview

This case report describes the successful treatment of an 11-year-old boy with metastatic ALK-rearranged lung adenocarcinoma using ceritinib. While ALK inhibitors are effective for treating ALK-rearranged non-small cell lung cancers, there is limited data on their use in pediatric patients. This case provides evidence for the potential efficacy and tolerability of ceritinib in this patient population.
Paper Details　
Original Abstract of the Article :
Anaplastic lymphoma kinase (ALK) inhibitors have significant efficacies in ALK-rearranged non-small cell lung cancers (NSCLC). In regard to pediatric NSCLC patients, however, there is a paradox in that on the one hand, they may have a higher probability of ALK-rearrangement positive, but on the othe...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.lungcan.2022.12.014

データ提供：米国国立医学図書館（NLM）

Ceritinib: A Potential Breakthrough in Pediatric Lung Cancer

Anaplastic lymphoma kinase (ALK) inhibitors have emerged as promising treatments for ALK-rearranged non-small cell lung cancer (NSCLC). However, there is limited data on their efficacy in pediatric patients with NSCLC. This research presents a case report of an 11-year-old boy diagnosed with metastatic ALK-rearranged lung adenocarcinoma who achieved a near-complete response to ceritinib treatment. This case highlights the potential of ALK inhibitors for treating pediatric lung cancer and provides valuable information for future research and clinical practice.

Ceritinib: A Glimmer of Hope for Pediatric Lung Cancer

This case report is a promising sign for children with ALK-rearranged lung cancer. Ceritinib's effectiveness in this young patient suggests that ALK inhibitors may offer a viable treatment option for this challenging disease.

Ceritinib: A Potential Lifeline for Children with Cancer

This research provides a ray of hope for children facing a difficult diagnosis of lung cancer. It suggests that ALK inhibitors, like ceritinib, could offer a potential path towards remission and improved quality of life.

Dr.Camel's Conclusion

This case report is a testament to the enduring power of hope and innovation in the face of challenging diseases. It's like finding a hidden oasis of hope in the vast desert of childhood cancer. Ceritinib offers a potential lifeline for children battling this disease, and we are hopeful that further research will bring even more breakthroughs in the future.

Date :
  1. Date Completed 2023-02-07
  2. Date Revised 2023-02-14
Further Info :

Pubmed ID

36640634

DOI: Digital Object Identifier

10.1016/j.lungcan.2022.12.014

Related Literature

Article Analysis
・Side Effects of ceritinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.